ClinicalTrials.gg
TerminatedNCT04024436Updated Nov 13, 2025Results posted

A Study of TAS-120 in Patients With Metastatic Breast Cancer

A Phase 2 interventional study of Futibatinib and Futibatinib plus Fulvestrant in Metastatic Breast Cancer, FGFR 1 High Amplification and FGFR2 Amplification, sponsored by Taiho Oncology, Inc.. Terminated at 37 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-13.

Sponsored by Taiho Oncology, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Why this study was terminated
The Sponsor decided to discontinue the study due to strategic considerations and not due to any safety-related concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 95 studies testing fulvestrant in Breast Neoplasms — 13 open to participants now, 23 under way, 5 of them phase 3. Fulvestrant · Breast Neoplasms.

Enrollment
49th of 94
64 · median 71
Started
2020
with 3 others
Phase 2
59 of 95
8 open now
Registered
71st of 95
by date

Among the 95 studies testing fulvestrant in Breast Neoplasms, this one is the 49th largest by enrollment of the 94 interventional ones that give a count, is one of 4 that started in 2020, is one of 59 in phase 2, and was the 71st registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

13 of the 95 studies testing fulvestrant in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About fulvestrant

Fulvestrant: first FDA approval 2002 (FASLODEX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies testing fulvestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of the trial is to evaluate a patient's response to a Fibroblast Growth Factor Receptor (FGFR) inhibitor, futibatinib (TAS-120), used either alone or in combination with the hormonal therapy, fulvestrant. This study will be conducted in patients with metastatic breast cancer who have specific Fibroblast Growth Factor Receptor gene abnormalities and who have previously received conventional therapies to treat their breast cancer, or who are not able to tolerate certain cancer therapies. This study will also evaluate the safety of taking futibatinib, or futibatinib and fulvestrant, by learning about the potential side effects.

Read the detailed description

This is a Phase 2, open-label, non-randomized, multicenter study designed to evaluate the efficacy and safety of futibatinib (TAS-120) and futibatinib + fulvestrant in up to 168 adult patients with locally advanced/metastatic breast cancer harboring FGFR gene amplifications. Patients will be enrolled to 1 of 4 treatment cohorts based on diagnosis and FGFR gene amplification status, and will receive either single agent futibatinib in Cohorts 1-3 or futibatinib plus fulvestrant in Cohort 4, as follows:

  • Cohort 1 - HR+ HER2- Measurable Disease w/ FGFR2 Amplification
  • Cohort 2 - TNBC Measurable Disease w/ FGFR2 Amplification
  • Cohort 3 - HR+ HER2- or TNBC Non-Measurable Disease w/ FGFR2 Amplification
  • Cohort 4 - HR+ HER2- Measurable Disease w/ FGFR1 Amplification
03

Conditions studied

  • Metastatic Breast Cancer
  • FGFR 1 High Amplification
  • FGFR2 Amplification

Browse trials for

Keywords

  • Futibatinib
  • Metastatic Breast Cancer
  • FGFR
  • TAS-120
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written
  2. Age ≥ 18 years of age
  3. or cytologically confirmed recurrent locally advanced or breast cancer not amenable to treatment with curative intent, and the following cohort specific criteria:

    A. Cohort 1

    • HR+ - breast cancer harboring an FGFR2 gene amplification.
    • per (RECIST) Version 1.1
    • Has received 1-3 prior endocrine-containing therapies and up to 2 prior chemotherapy regimens for advanced/metastatic disease
    • Has received prior treatment with a CDK4/6 inhibitor or is ineligible for such treatment

    B. Cohort 2

    • TNBC harboring an FGFR2 gene amplification
    • Measurable disease per RECIST 1.1
    • Has received at least 1 prior chemotherapy or chemotherapy/immunotherapy (/PD-1 inhibitors) regimen for advanced/metastatic disease

    C. Cohort 3

    • TNBC or HR+ HER2- breast cancer harboring an FGFR2 gene amplification
    • Non measurable, evaluable disease per RECIST 1.1. Patients with bone-only disease must have lytic or mixed lytic-blastic lesions
    • Other criteria for either HR+ HER2- breast cancer or TNBC should be met as described for Cohort 1 and 2, respectively

    D. Cohort 4

    • HR+ HER2- breast cancer harboring an FGFR1 high-level gene amplification
    • Measurable disease per RECIST 1.1
    • Has received 1-2 prior endocrine-containing therapies and no more than 1 prior chemotherapy regimen for advanced/metastatic disease. Prior treatment with fulvestrant is not permitted.
    • Has received prior treatment with a CDK4/6 inhibitor or is ineligible for such treatment
    • Pre/peri-menopausal patients must be on goserelin
  4. (ECOG) performance status 0 or 1
  5. Archival or (preferably) fresh tumor tissue must be available
  6. Adequate organ function

Exclusion criteria

Exclusion Criteria:

  1. History and/or current evidence of any of the following disorders:

    1. Non-tumor related alteration of the calcium-phosphorus homeostasis that is considered
    2. Ectopic mineralization/calcification, including but not limited to soft tissue, kidneys, intestine, or myocardia and lung, considered clinically significant
    3. Retinal or corneal disorder confirmed by retinal/corneal examination and considered clinically significant
  2. Prior treatment with an FGFR inhibitor
  3. A serious illness or medical condition(s)
  4. that are untreated or clinically or radiologically unstable
  5. Pregnant or lactating female
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Futibatinib (Cohort 1)

    Participants with advanced or metastatic hormone receptor - positive (HR+), human epidermal growth factor receptor 2 - negative (HER2-) breast cancer, harboring fibroblast growth factor receptor 2 (FGFR2) gene amplification, with measurable disease received futibatinib, 20 milligrams (mg), oral tablets, once daily for a continuous 28-day cycle up to maximum of 244 days.

    Drug: Futibatinib

  • Experimental
    Futibatinib (Cohort 2)

    Participants with advanced or metastatic triple negative breast cancer (TNBC), harboring FGFR2 gene amplification, with measurable disease received futibatinib, 20 mg, oral tablets, once daily for a continuous 28-day cycle up to maximum of 1066 days.

    Drug: Futibatinib

  • Experimental
    Futibatinib (Cohort 3)

    Participants with advanced or metastatic HR+, HER2- or TNBC, harboring FGFR2 gene amplification, with non-measurable disease received futibatinib, 20 mg, oral tablets, once daily for a continuous 28-day cycle up to maximum of 252 days.

    Drug: Futibatinib

  • Experimental
    Futibatinib Plus Fulvestrant (Cohort 4)

    Participants with advanced or metastatic HR+ HER2- breast cancer, harboring FGFR1 gene amplification, with measurable disease, received futibatinib, 20 mg, oral tablets, once daily for a continuous 28-day cycle up to maximum of 645 days. They also received intramuscular (IM) fulvestrant 500 mg on Days 1 and 15 of Cycle 1 and Day 1 of every subsequent cycle up to maximum of 618 days.

    Drug: Futibatinib plus Fulvestrant

Interventions

  • Futibatinib 20mg once daily on a 28-day cycle

    Also known as: TAS-120

  • DrugFutibatinib plus Fulvestrant

    Drug pages: Futibatinib · Fulvestrant

    Futibatinib 20mg once daily on a 28-day cycle and fulvestrant 500 mg administered intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on a 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) - Cohorts 1, 2

    ORR was defined as the percentage of participants with a confirmed response of either complete response (CR) or partial response (PR), based on Investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. ORR was calculated based on the best overall response recorded from the start of treatment until progressive disease or start of subsequent new anticancer treatment. Percentages were rounded off to the nearest single decimal place.

    Time frame: At the end of every 2 cycles until disease progression (up to 40 months)

  2. Clinical Benefit Rate (CBR) - Cohort 3

    CBR was defined as the percentage of participants with a confirmed response of CR or stable disease (SD) lasting at least 24 weeks, based on Investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10mm. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), referencing the smallest sum diameters while on study. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. PD was defined as at least a 20% increase in the sum of diameters of the target lesions, taking as a reference the smallest sum on study, including the baseline sum. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Definitive new lesion presence also indicates progression. Percentages were rounded off to the nearest

    Time frame: At the end of every 2 cycles until disease progression (up to 40 months)

  3. 6-month Progression-free Survival (PFS) Rate - Cohort 4

    The 6-month PFS rate was defined as the percentage of participants who are alive and progression-free 6 months after the first dose of study drug. Percentages were rounded off to the nearest single decimal place.

    Time frame: At the end of every 2 cycles until disease progression (up to 6 months)

Secondary outcomes

  1. Complete Response (CR) Rate - Cohort 3

    CR rate was defined as the percentage of participants who achieved CR. CR was defined as disappearance of all targets. Any pathological lymph node must have reduction in short axis to \<10 mm. Percentages were rounded off to the nearest single decimal place.

    Time frame: At the end of every 2 cycles until disease progression (up to 40 months)

  2. Overall Response Rate (ORR) - Cohort 4

    ORR was defined as the percentage of participants with a confirmed response of either CR or PR, based on Investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. ORR was calculated based on the best overall response recorded from the start of treatment until progressive disease or start of subsequent new anticancer treatment. Percentages were rounded off to the nearest single decimal place.

    Time frame: At the end of every 2 cycles until disease progression (up to 40 months)

  3. Clinical Benefit Rate (CBR) - Cohort 1,2, and 4

    CBR was defined as the percentage of participants with a confirmed response of CR, PR or SD lasting at least 24 weeks, based on Investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, referencing the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of diameters of the target lesions, taking as a reference the smallest sum on study, including the baseline sum. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Definitive new lesion presence also indicates progression. Percentages were rounded off to the nearest single decimal place.

    Time frame: At the end of every 2 cycles until disease progression (up to 40 months)

  4. 6-month PFS Rate - Cohorts 1,2, and 3

    The 6-month PFS rate was defined as the percentage of participants who are alive and progression-free 6 months after the first dose of study drug. Percentages were rounded off to the nearest single decimal place.

    Time frame: At the end of every 2 cycles until disease progression (up to 6 months)

  5. Progression Free Survival (PFS)

    PFS was defined as the time from the first dose of study therapy to the date of death (any cause) or disease progression based on investigator assessment, whichever occurs first. The PFS was analyzed using a Kaplan-Meier method with PFS time being censored on the date of the last disease assessment. The 95% CI for median PFS was provided using the Kaplan-Meier procedure.

    Time frame: At the end of every 2 cycles until disease progression (up to 40 months)

  6. Duration of Response (DOR)

    DOR was defined as the time from the first documentation of objective response to the to the date of death (any cause) or disease progression, based on Investigator assessment, whichever occurs first. Objective response was defined as participants with a confirmed response of either CR or PR, based on Investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. DOR was estimated using the Kaplan-Meier method.

    Time frame: At the end of every 2 cycles until disease progression (up to 40 months)

  7. Overall Survival (OS)

    OS was defined as the time (in months) from the date of first dose of the study drug to the date of death. Participants without a documented death date were censored on the last date they were known to be alive. The OS was presented using a Kaplan-Meier estimate. The 95% CI for median OS was provided using the Kaplan-Meier procedure.

    Time frame: Up to 40 months

  8. Number of Participants With Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a clinical study participant and does not necessarily have a causal relationship with the study drug.

    Time frame: From the first dose of study drug up to 30 days after the last dose (Up to 40 months)

  9. Number of Participants With Dose Limiting Toxicities (DLTs) - Cohort 4

    A DLT was defined as any AE that occurs during Cycle 1 that is not clearly attributable to an extraneous cause, such as an underlying disease, occurring in Cycle 1, and meeting at least one of the criteria defined in the protocol. An AE is defined as any untoward medical occurrence in a clinical study participant and does not necessarily have a causal relationship with the study drug.

    Time frame: Cycle 1 (cycle length= 28 days)

07

Results

Posted Nov 13, 2025
Limitations and caveats
The Sponsor decided to discontinue the study due to strategic considerations and not due to any safety-related concerns.

Participant flow

Participants took part in the study from 28 January 2020 to 06 September 2023.

Participant flow — Overall Study
MilestoneFutibatinib (Cohort 1)Futibatinib (Cohort 2)Futibatinib (Cohort 3)Futibatinib Plus Fulvestrant (Cohort 4)
Started1721422
Completed0000
Not completed1721422
Withdrew: Death101427
Withdrew: Loss to follow up1001
Withdrew: Withdrawal of consent2001
Withdrew: Study termination by sponsor46211
Withdrew: Reason not specified0102

Outcome measures

PrimaryObjective Response Rate (ORR) - Cohorts 1, 2

ORR was defined as the percentage of participants with a confirmed response of either complete response (CR) or partial response (PR), based on Investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. ORR was calculated based on the best overall response recorded from the start of treatment until progressive disease or start of subsequent new anticancer treatment. Percentages were rounded off to the nearest single decimal place.

Time frame:
At the end of every 2 cycles until disease progression (up to 40 months)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) - Cohorts 1, 2
percentage of participantsFutibatinib (Cohort 1)Futibatinib (Cohort 2)
Objective Response Rate (ORR) - Cohorts 1, 20 (0.0 to 19.5)9.5 (1.2 to 30.4)
PrimaryClinical Benefit Rate (CBR) - Cohort 3

CBR was defined as the percentage of participants with a confirmed response of CR or stable disease (SD) lasting at least 24 weeks, based on Investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10mm. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), referencing the smallest sum diameters while on study. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. PD was defined as at least a 20% increase in the sum of diameters of the target lesions, taking as a reference the smallest sum on study, including the baseline sum. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Definitive new lesion presence also indicates progression. Percentages were rounded off to the nearest

Time frame:
At the end of every 2 cycles until disease progression (up to 40 months)
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR) - Cohort 3
percentage of participantsFutibatinib (Cohort 3)
Clinical Benefit Rate (CBR) - Cohort 350.0 (6.8 to 93.2)
Primary6-month Progression-free Survival (PFS) Rate - Cohort 4

The 6-month PFS rate was defined as the percentage of participants who are alive and progression-free 6 months after the first dose of study drug. Percentages were rounded off to the nearest single decimal place.

Time frame:
At the end of every 2 cycles until disease progression (up to 6 months)
Reported as:
Number · percentage of participants
6-month Progression-free Survival (PFS) Rate - Cohort 4
percentage of participantsFutibatinib Plus Fulvestrant (Cohort 4)
6-month Progression-free Survival (PFS) Rate - Cohort 445.5 (24.4 to 67.8)
SecondaryComplete Response (CR) Rate - Cohort 3

CR rate was defined as the percentage of participants who achieved CR. CR was defined as disappearance of all targets. Any pathological lymph node must have reduction in short axis to \<10 mm. Percentages were rounded off to the nearest single decimal place.

Time frame:
At the end of every 2 cycles until disease progression (up to 40 months)
Reported as:
Number · percentage of participants
Complete Response (CR) Rate - Cohort 3
percentage of participantsFutibatinib (Cohort 3)
Complete Response (CR) Rate - Cohort 30 (0.0 to 60.2)
SecondaryOverall Response Rate (ORR) - Cohort 4

ORR was defined as the percentage of participants with a confirmed response of either CR or PR, based on Investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. ORR was calculated based on the best overall response recorded from the start of treatment until progressive disease or start of subsequent new anticancer treatment. Percentages were rounded off to the nearest single decimal place.

Time frame:
At the end of every 2 cycles until disease progression (up to 40 months)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) - Cohort 4
percentage of participantsFutibatinib Plus Fulvestrant (Cohort 4)
Overall Response Rate (ORR) - Cohort 418.2 (5.2 to 40.3)
SecondaryClinical Benefit Rate (CBR) - Cohort 1,2, and 4

CBR was defined as the percentage of participants with a confirmed response of CR, PR or SD lasting at least 24 weeks, based on Investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, referencing the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of diameters of the target lesions, taking as a reference the smallest sum on study, including the baseline sum. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Definitive new lesion presence also indicates progression. Percentages were rounded off to the nearest single decimal place.

Time frame:
At the end of every 2 cycles until disease progression (up to 40 months)
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR) - Cohort 1,2, and 4
percentage of participantsFutibatinib (Cohort 1)Futibatinib (Cohort 2)Futibatinib Plus Fulvestrant (Cohort 4)
Clinical Benefit Rate (CBR) - Cohort 1,2, and 411.8 (1.5 to 36.4)23.8 (8.2 to 47.2)50.0 (28.2 to 71.8)
Secondary6-month PFS Rate - Cohorts 1,2, and 3

The 6-month PFS rate was defined as the percentage of participants who are alive and progression-free 6 months after the first dose of study drug. Percentages were rounded off to the nearest single decimal place.

Time frame:
At the end of every 2 cycles until disease progression (up to 6 months)
Reported as:
Number · percentage of participants
6-month PFS Rate - Cohorts 1,2, and 3
percentage of participantsFutibatinib (Cohort 1)Futibatinib (Cohort 2)Futibatinib (Cohort 3)
6-month PFS Rate - Cohorts 1,2, and 35.9 (0.1 to 28.7)19.0 (5.4 to 41.9)50.0 (6.8 to 93.2)
SecondaryProgression Free Survival (PFS)

PFS was defined as the time from the first dose of study therapy to the date of death (any cause) or disease progression based on investigator assessment, whichever occurs first. The PFS was analyzed using a Kaplan-Meier method with PFS time being censored on the date of the last disease assessment. The 95% CI for median PFS was provided using the Kaplan-Meier procedure.

Time frame:
At the end of every 2 cycles until disease progression (up to 40 months)
Reported as:
Median · months
Progression Free Survival (PFS)
monthsFutibatinib (Cohort 1)Futibatinib (Cohort 2)Futibatinib (Cohort 3)Futibatinib Plus Fulvestrant (Cohort 4)
Progression Free Survival (PFS)3.7 (1.7 to 5.1)1.9 (1.6 to 4.0)12.4 (1.9 to NA)7.2 (2.1 to 7.6)
SecondaryDuration of Response (DOR)

DOR was defined as the time from the first documentation of objective response to the to the date of death (any cause) or disease progression, based on Investigator assessment, whichever occurs first. Objective response was defined as participants with a confirmed response of either CR or PR, based on Investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. DOR was estimated using the Kaplan-Meier method.

Time frame:
At the end of every 2 cycles until disease progression (up to 40 months)
Reported as:
Median · months
Duration of Response (DOR)
monthsFutibatinib (Cohort 1)Futibatinib (Cohort 2)Futibatinib (Cohort 3)Futibatinib Plus Fulvestrant (Cohort 4)
Duration of Response (DOR)—3.38 (3.1 to 3.7)—6.34 (3.3 to 16.7)
SecondaryOverall Survival (OS)

OS was defined as the time (in months) from the date of first dose of the study drug to the date of death. Participants without a documented death date were censored on the last date they were known to be alive. The OS was presented using a Kaplan-Meier estimate. The 95% CI for median OS was provided using the Kaplan-Meier procedure.

Time frame:
Up to 40 months
Reported as:
Median · months
Overall Survival (OS)
monthsFutibatinib (Cohort 1)Futibatinib (Cohort 2)Futibatinib (Cohort 3)Futibatinib Plus Fulvestrant (Cohort 4)
Overall Survival (OS)16.5 (8.1 to NA)10.2 (6.1 to 21.8)30.4 (12.4 to NA)23.9 (20.6 to NA)
SecondaryNumber of Participants With Adverse Events (AEs)

An AE is defined as any untoward medical occurrence in a clinical study participant and does not necessarily have a causal relationship with the study drug.

Time frame:
From the first dose of study drug up to 30 days after the last dose (Up to 40 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsFutibatinib (Cohort 1)Futibatinib (Cohort 2)Futibatinib (Cohort 3)Futibatinib Plus Fulvestrant (Cohort 4)
Number of Participants With Adverse Events (AEs)1721422
SecondaryNumber of Participants With Dose Limiting Toxicities (DLTs) - Cohort 4

A DLT was defined as any AE that occurs during Cycle 1 that is not clearly attributable to an extraneous cause, such as an underlying disease, occurring in Cycle 1, and meeting at least one of the criteria defined in the protocol. An AE is defined as any untoward medical occurrence in a clinical study participant and does not necessarily have a causal relationship with the study drug.

Time frame:
Cycle 1 (cycle length= 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities (DLTs) - Cohort 4
ParticipantsFutibatinib Plus Fulvestrant (Cohort 4)
Number of Participants With Dose Limiting Toxicities (DLTs) - Cohort 40

Adverse events

Collected over From the first dose of study drug up to 30 days after the last dose (Up to 40 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Futibatinib (Cohort 1)10/17 (58.8%)4/17 (23.5%)16/17 (94.1%)
Futibatinib (Cohort 2)14/21 (66.7%)5/21 (23.8%)21/21 (100%)
Futibatinib (Cohort 3)2/4 (50%)1/4 (25%)4/4 (100%)
Futibatinib Plus Fulvestrant (Cohort 4)7/22 (31.8%)4/22 (18.2%)22/22 (100%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventFutibatinib (Cohort 1)Futibatinib (Cohort 2)Futibatinib (Cohort 3)Futibatinib Plus Fulvestrant (Cohort 4)
Pathological fractureMusculoskeletal and connective tissue disorders0/170/211/40/22
NauseaGastrointestinal disorders1/170/210/40/22
COVID-19Infections and infestations1/170/210/40/22
HyperphosphataemiaMetabolism and nutrition disorders1/170/210/40/22
Acute promyelocytic leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/170/210/40/22
Acute kidney injuryRenal and urinary disorders1/171/210/40/22
InfluenzaInfections and infestations0/171/210/40/22
Urinary tract infectionInfections and infestations0/171/210/40/22
Urinary tract obstructionRenal and urinary disorders0/171/210/40/22
ArthralgiaMusculoskeletal and connective tissue disorders0/171/210/40/22
Most frequent other events
Showing 10 of 112
Most frequent other events
EventFutibatinib (Cohort 1)Futibatinib (Cohort 2)Futibatinib (Cohort 3)Futibatinib Plus Fulvestrant (Cohort 4)
HyperphosphataemiaMetabolism and nutrition disorders13/1718/213/421/22
FatigueGeneral disorders4/177/213/47/22
ConstipationGastrointestinal disorders8/179/211/413/22
Alanine aminotransferase increasedInvestigations4/172/210/413/22
AlopeciaSkin and subcutaneous tissue disorders4/173/211/413/22
Aspartate aminotransferase increasedInvestigations7/175/210/411/22
PruritusSkin and subcutaneous tissue disorders3/171/212/41/22
ArthralgiaMusculoskeletal and connective tissue disorders2/174/212/47/22
Muscle spasmsMusculoskeletal and connective tissue disorders3/173/212/43/22
DysgeusiaNervous system disorders1/170/212/45/22

Baseline characteristics

All treated population included all enrolled participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Futibatinib (Cohort 1)Futibatinib (Cohort 2)Futibatinib (Cohort 3)Futibatinib Plus Fulvestrant (Cohort 4)Total
Mean59.8 ± 11.4251.4 ± 14.5060.8 ± 5.7452.7 ± 12.6854.7 ± 13.01
Sex: Female, Male
Sex: Female, Male(Participants)Futibatinib (Cohort 1)Futibatinib (Cohort 2)Futibatinib (Cohort 3)Futibatinib Plus Fulvestrant (Cohort 4)Total
Female172142264
Male00000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Futibatinib (Cohort 1)Futibatinib (Cohort 2)Futibatinib (Cohort 3)Futibatinib Plus Fulvestrant (Cohort 4)Total
Hispanic or Latino11024
Not Hispanic or Latino151541347
Unknown or Not Reported150713
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Futibatinib (Cohort 1)Futibatinib (Cohort 2)Futibatinib (Cohort 3)Futibatinib Plus Fulvestrant (Cohort 4)Total
American Indian or Alaska Native00000
Asian10012
Native Hawaiian or Other Pacific Islander01001
Black or African American21014
White141241646
More than one race00000
Unknown or Not Reported070411
08

Study locations

37 sites
  • Mayo Clinic - AZ
    Phoenix, Arizona 85054, United States
  • USCF
    San Francisco, California 94115, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33901, United States
  • Mayo Clinic - FL
    Jacksonville, Florida 32224, United States
  • Florida Cancer Specialists
    St. Petersburg, Florida 33705, United States
  • Florida Cancer Specialists
    Tallahassee, Florida 32308, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Florida Cancer Specialists
    West Palm Beach, Florida 33401, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • BIDMC
    Boston, Massachusetts 02115, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Mayo Clinic - MN
    Rochester, Minnesota 55905, United States
  • HCA Midwest Health
    Kansas City, Missouri 64132, United States
  • Tennessee Oncology
    Chattanooga, Tennessee 37404, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • UT Southwestern
    Dallas, Texas 75390, United States
  • MD Anderson
    Houston, Texas 77030, United States
  • Tom Baker Cancer Center
    Calgary, T2N 4N2, Canada
  • SunnyBrook Health Sciences
    Toronto, M4N 3M5, Canada
  • Institut Gustave Roussy
    Villejuif, Cedex 94805, France
  • Centre Leon Berard
    Lyon, 69008, France
  • AOU Policlinico - Vittorio Emanuele
    Catania, 95123, Italy
  • Istituto Europeo Di Oncologia - IEO
    Milan, 20141, Italy
  • AOU Modena Policlinico
    Modena, Italy
  • Ospedale E. Agnelli
    Pinerolo, 10064, Italy
  • Azienda Ospedaliero Universitaria Pisana
    Pisa, 56126, Italy
  • Istituto Nazionale Tumori Regina Elena
    Roma, 00144, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Roma, 00168, Italy
  • Centro Hospitalar Universitario Lisboa Norte
    Lisbon, 1649-035, Portugal
  • Porto University
    Porto, 4099-001, Portugal
  • Instituto Portugues de Oncologia do Porto
    Porto, 4200-072, Portugal
  • Vall d'Hebron
    Barcelona, 08035, Spain
  • University Gregorio Marañon
    Madrid, 28007, Spain
  • START Madrid - CIOCC
    Madrid, 28050, Spain
  • HCA Healthcare UK
    London, England W1G 6AD, United Kingdom
  • The Christie NHS Foundation Trust
    Manchester, England M20 4BX, United Kingdom
  • The Royal Marsden NHS Foundation Trust
    Sutton, England SM2 5PT, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in May 2023, 40 months.

Results were first posted in Nov 2025, 2 years 5 months after primary completion. A results delay was requested in May 2024.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2019
First posted
Jul 18, 2019
StartActual
Jan 28, 2020
Primary completionActual
May 31, 2023
CompletionActual
Sep 6, 2023
Results delay requested
May 23, 2024
Results first posted
Nov 13, 2025
Last update
Nov 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04024436
Responsible party
Sponsor
First posted
Jul 18, 2019
Start date
Jan 28, 2020
Primary completion
May 31, 2023
Completion
Sep 6, 2023
Results posted
Nov 13, 2025
Last update
Nov 13, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Futibatinib · Fulvestrant

Start the discussion